Discover some of the new atopic dermatitis treatments in clinical development that could overcome existing challenges in the ...
When Evommune went public late last year, it said data from a proof-of-concept test of one of its atopic dermatitis drug candidates would come in the first half of 2026. The results are in, with the ...
The MarketWatch News Department was not involved in the creation of this content. In the Phase 3 ADorable-1 study, 63% of patients achieved meaningful skin improvement (EASI-75) and 44% achieved clear ...
- ZL-1503, a promising treatment for moderate-to-severe atopic dermatitis and other Type 2 helper T-cell (Th2)-driven diseases, strengthens Zai Lab’s growing global pipeline - ZL-1503 originated from ...
The study1 by Emma Guttman-Yassky and colleagues represents an important and innovative contribution to the evolving treatment landscape of moderate-to-severe atopic dermatitis, particularly by ...
In this episode, the panel discusses the next wave of biologic development in atopic dermatitis, including bispecific ...
Apollo Therapeutics’ $15 million bet on Avalo’s anti-IL-18 monoclonal antibody appears to have paid off after the candidate aced a phase 2 trial in atopic dermatitis (AD). The phase 2a study involved ...
Pfizer is ramping up plans for tilrekimig after a phase 2 win raised hopes that the once-monthly trispecific antibody could hold its own against approved eczema drugs. The Big Pharma evaluated three ...
In the Phase 3 ADorable-1 study, 63% of patients achieved meaningful skin improvement (EASI-75) and 44% achieved clear or almost clear skin (IGA 0,1) at Week 16 In key secondary endpoints, 39% of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results